EMPHASIS-HF
2011
Eplerenone in Mild Patients Hospitalisation and Survival Study in Heart Failure
In 2,737 patients with mild HFrEF (NYHA II, EF ≤ 35 %), eplerenone reduced cardiovascular death or heart-failure hospitalisation compared with placebo.
Result
Efficacy: CV death or HF hospitalisationHR 0.63
Below 1 favours eplerenone, above 1 favours placebo.
- Absolute difference
- 7.6 points
The absolute difference is derived from the event rates.
- Subtopic
- MRA
- Design
- Double-blind RCT, stopped early
- Relevance
- Important: one of several pillars.
- Source
- Zannad F, et al. N Engl J Med. 2011;364(1):11-21.doi 10.1056/NEJMoa1009492
Discussion & critique
Extended MRA benefit from severe (RALES) to mild HF. Hyperkalaemia mandates monitoring; eplerenone avoids the gynaecomastia of spironolactone.